- ALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program for gout and chronic kidney disease; initial data expected in Q4 2021
- June KOL webinar highlighted the unmet need in gout and potential for ALLN-346
- Updated…
